

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG(19) Weltorganisation für geistiges Eigentum
Internationales Büro(43) Internationales Veröffentlichungsdatum
30. August 2001 (30.08.2001)

PCT

(10) Internationale Veröffentlichungsnummer
WO 01/62747 A1(51) Internationale Patentklassifikation⁷: C07D 277/60,
A61K 31/428, A61P 3/04

(21) Internationales Aktenzeichen: PCT/EP01/01553

(22) Internationales Anmeldedatum:
13. Februar 2001 (13.02.2001)

(25) Einreichungssprache: Deutsch


(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:
100 09 311.6 26. Februar 2000 (26.02.2000) DE(71) Anmelder: AVENTIS PHARMA DEUTSCHLAND
GMBH [DE/DE]; Brüningstrasse 50, 65929 Frankfurt
(DE).(72) Erfinder: JAEHNE, Gerhard; Seebachstrasse 22, 65929
Frankfurt (DE). LANG, Hans-Jochen; Rüdesheimer
Strasse 7, 65719 Hofheim (DE). GOSSEL, Matthias;
Im Lorsbachtal 17a, 65719 Hofheim (DE). BICKEL,
Martin; Mittelstedter Weg 3, 61348 Bad Homburg (DE).(81) Bestimmungsstaaten (national): AE, AG, AL, AM, AT,
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.(84) Bestimmungsstaaten (regional): ARIPO-Patent (GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW),
eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), europäisches Patent (AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),
OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML,
MR, NE, SN, TD, TG).

Veröffentlicht:

- mit internationalem Recherchenbericht
- vor Ablauf der für Änderungen der Ansprüche geltenden
Frist; Veröffentlichung wird wiederholt, falls Änderungen
eintreffen

Zur Erklärung der Zweibuchstaben-Codes, und der anderen
Abkürzungen wird auf die Erklärungen ("Guidance Notes on
Codes and Abbreviations") am Anfang jeder regulären Ausgabe
der PCT-Gazette verwiesen.

(54) Title: 8,8A-DIHYDRO-INDENO[1,2-D]THIAZOLE DERIVATIVES WITH A SULPHONAMIDO OR SULPHONO SUB-
STITUENT IN THE 2 POSITION, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF AS A MEDICAMENT(54) Bezeichnung: 8,8A-DIHYDRO-INDENO[1,2-D]THIAZOL-DERIVATE, DIE IN 2-STELLUNG EINEN SUBSTITUENTEN
MIT EINER SULFONAMIDSTRUKTUR ODER SULFONSTRUKTUR TRAGEN; VERFAHREN ZU IHRER HERSTELLUNG
UND IHRE VERWENDUNG ALS ARZNEIMITTEL

(57) Abstract: The invention relates to polycyclic dihydrothiazoles, the physiologically acceptable salts thereof and the physiologically functional derivatives thereof. Compounds of formula (I), where the substituents have the given meanings, the physiologically acceptable salts and methods for production thereof are disclosed. The compounds are suitable as, for example, anorectics.

(57) Zusammenfassung: Die Erfindung betrifft polycyclische Dihydrothiazole sowie deren physiologisch verträgliche Salze und physiologisch funktionelle Derivate. Es werden Verbindungen der Formel (I), worin die Reste die angegebenen Bedeutungen haben, sowie deren physiologisch verträglichen Salze und Verfahren zu deren Herstellung

beschrieben. Die Verbindungen eignen sich z.B. als Anorektika.

WO 01/62747 A1

Description


8,8a-Dihydroindeno[1,2-d]thiazole derivatives which carry in the 2-position a
 5 substituent having a sulfonamide structure or sulfone structure; processes for their preparation and their use as medicaments, may be provided.

One embodiment may relate to polycyclic dihydrothiazoles and their physiologically
 10 acceptable salts and physiologically functional derivatives.

Thiazolidine derivatives having anorectic action have already been described in
 the prior art (Austrian Patent No. 365181).

In another embodiment, further compounds having a therapeutically useful anorectic action may
 be provided.

Accordingly, a first aspect of the present invention provides compounds of the
 formula I



I

20 in which

R1, R1' independently of one another are H, F, Cl, Br, I, CF₃, NO₂, CN,
 COOH, COO(C₁-C₆)-alkyl, CONH₂, CONH(C₁-C₆)-alkyl,
 CON[(C₁-C₆)-alkyl]₂, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl,
 25 O-(C₁-C₆)-alkyl, where in the alkyl radicals one or more, or all the
 hydrogen(s) may be replaced by fluorine, or one hydrogen may be

replaced by OH, OC(O)CH₃, OC(O)H, O-CH₂-Ph, NH₂, NH-CO-CH₃
or N(COOCH₂Ph)₂;

are SO₂-NH₂, SO₂NH(C₁-C₆)-alkyl, SO₂N[(C₁-C₆)-alkyl]₂,

S-(C₁-C₆)-alkyl, S-(CH₂)_n-phenyl, SO-(C₁-C₆)-alkyl, SO-

(CH₂)_n-phenyl, SO₂-(C₁-C₆)-alkyl, SO₂-(CH₂)_n-phenyl, where n can
be 0-6 and the phenyl radical can be substituted up to two times by F,
Cl, Br, OH, CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl,
NH₂;

are NH₂, NH-(C₁-C₆)-alkyl, N[(C₁-C₆)-alkyl]₂, NH(C₁-C₇)-acyl,

phenyl, biphenyl, O-(CH₂)_n-phenyl, where n can be 0-6, 1- or
2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl or 2- or 3-thienyl, where
the phenyl, biphenyl, naphthyl, pyridyl, furanyl or thienyl rings can in
each case be substituted one to three times by F, Cl, Br, I, OH, CF₃,
NO₂, CN, OCF₃, O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, NH₂, NH(C₁-C₆)-

alkyl, N[(C₁-C₆)-alkyl]₂, SO₂-CH₃, COOH, COO-(C₁-C₆)-alkyl,

CONH₂;

are 1,2,3-triazol-5-yl, where the triazole ring can be substituted in the
1-, 2- or 3-position by methyl or benzyl;

are tetrazol-5-yl, where the tetrazole ring can be substituted in the 1-
or 2-position by methyl or benzyl;

R₂

is H, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, (CH₂)_n-phenyl, (CH₂)_n-thienyl,
(CH₂)_n-pyridyl, (CH₂)_n-furyl, C(O)-(C₁-C₆)-alkyl, C(O)-(C₃-C₆)-
cycloalkyl, C(O)-(CH₂)_n-phenyl, C(O)-(CH₂)_n-thienyl,

C(O)-(CH₂)_n-pyridyl, C(O)-(CH₂)_n-furyl, where n can be 0-5 and in
which phenyl, thienyl, pyridyl and furyl can in each case be

substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH,
O-(C₁-C₆)-alkyl;

R3 is H, (C₁-C₆)-alkyl, F, CN, N₃, O-(C₁-C₆)-alkyl, (CH₂)_n-phenyl,
5 (CH₂)_n-thienyl, (CH₂)_n-pyridyl, (CH₂)_n-furyl, where n can be 0-5 and
in which phenyl, thienyl, pyridyl and furyl can in each case be
substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH,
O-(C₁-C₆)-alkyl;

is OC(O)CH₃, (C₂-C₆)-alkynyl, (C₂-C₆)-alkenyl, COO(C₁-C₆)-alkyl,
10 C(O)OH, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂;

R4 is (CH₂)_n-R5, where n can be 0-6;

R5 is phenyl, biphenyl, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or
15 3-thienyl, 2- or 3-furyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl,
1-pyrazolyl, 3- or 5-isoxazolyl, 2- or 3-pyrrolyl, 2- or 3-pyridazinyl, 2-,
4- or 5-pyrimidinyl, 2-pyrazinyl, 2-(1,3,5-triazinyl), 2- or
5-benzimidazolyl, 2-benzothiazolyl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl,
tetrazol-5-yl, indol-3-yl, indol-5-yl or N-methylimidazol-2-, -4- or -5-yl;

20 and R5 is substituted by

NH-SO₂-(C₁-C₆)-alkyl, NH-SO₂-phenyl, where the phenyl ring can be
substituted up to two times by F, Cl, CN, OH, (C₁-C₆)-alkyl,

O-(C₁-C₆)-alkyl, CF₃, COOH, COO(C₁-C₆)-alkyl, CONH₂;

(CH₂)_n-SO₂-(C₁-C₆)-alkyl, where n can be 1-6,

25 (CH₂)_m-SO₂-NH₂, (CH₂)_m-SO₂-NH-(C₁-C₆)-alkyl, (CH₂)_m-SO₂-

N[(C₁-C₆)-alkyl]₂ or (CH₂)_m-SO₂-N(=CH-N(CH₃)₂), where m can be
0-6;

and R5 can optionally additionally be substituted by F, Cl, Br, OH, CF₃, NO₂, CN,

OCF₃, O-(C₁-C₆)-alkyl, S-(C₁-C₆)-alkyl, SO-(C₁-C₆)-alkyl,

(C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, COOH, COO(C₁-C₆)-alkyl,

COO(C₃-C₆)-cycloalkyl, CONH₂, CONH(C₁-C₆)-alkyl,

CON[(C₁-C₆)-alkyl]₂, CONH(C₃-C₆)-cycloalkyl, NH₂,

NH-CO-(C₁-C₆)-alkyl, NH-CO-phenyl, pyrrolidin-1-yl, morpholin-1-yl,

piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH₂)_n-phenyl,

O-(CH₂)_n-phenyl, S-(CH₂)_n-phenyl, SO₂-(CH₂)_n-phenyl, where n can

be 0-3;

and their physiologically acceptable salts and physiologically functional derivatives.

Preference may be given to compounds of the formula I in which

R₁, R₁¹ independently of one another may be H, F, Cl, Br, I, CF₃, NO₂, CN,

COOH, COO(C₁-C₆)-alkyl, CONH₂, CONH(C₁-C₆)-alkyl,

CON[(C₁-C₆)-alkyl]₂, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl,

O-(C₁-C₆)-alkyl, where in the alkyl radicals one hydrogen may be

replaced by OH, OC(O)CH₃, OC(O)H, O-CH₂-Ph, NH₂, NH-CO-CH₃

or N(COOCH₂Ph)₂;

may be SO₂-NH₂, SO₂NH(C₁-C₆)-alkyl, SO₂N[(C₁-C₆)-alkyl]₂, S-(C₁-C₆)-

alkyl, S-(CH₂)_n-phenyl, SO-(C₁-C₆)-alkyl, SO-(CH₂)_n-phenyl,

SO₂-(C₁-C₆)-alkyl, SO₂-(CH₂)_n-phenyl, where n can be 0-6 and the

phenyl radical can be substituted up to two times by F, Cl, Br, OH,

CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, NH₂;

may be NH₂, NH-(C₁-C₆)-alkyl, N[(C₁-C₆)-alkyl]₂, NH(C₁-C₇)-acyl, phenyl,

biphenyl, $O-(CH_2)_n$ -phenyl, where n can be 0-6, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl or 2- or 3-thienyl where the phenyl, biphenyl, naphthyl, pyridyl, furanyl or thienyl rings can in each case be substituted one to 3 times by F, Cl, Br, I, OH, CF_3 , NO_2 , CN, OCF_3 , $O-(C_1-C_6)$ -alkyl, (C_1-C_6) -alkyl, NH_2 , $NH(C_1-C_6)$ -alkyl, $N[(C_1-C_6)$ -alkyl] $_2$, SO_2-CH_3 , $COOH$, $COO-(C_1-C_6)$ -alkyl, $CONH_2$; may be 1,2,3-triazol-5-yl, where the triazole ring can be substituted in the 1-, 2- or 3-position by methyl or benzyl; may be tetrazol-5-yl, where the tetrazole ring can be substituted in the 1- or 2-position by methyl or benzyl;

R2

may be H, (C_1-C_6) -alkyl, (C_3-C_6) -cycloalkyl, $(CH_2)_n$ -phenyl, $(CH_2)_n$ -thienyl, $(CH_2)_n$ -pyridyl, $(CH_2)_n$ -furyl, $C(O)-(C_1-C_6)$ -alkyl, $C(O)-(C_3-C_6)$ -cycloalkyl, $C(O)-(CH_2)_n$ -phenyl, $C(O)-(CH_2)_n$ -thienyl, $C(O)-(CH_2)_n$ -pyridyl, $C(O)-(CH_2)_n$ -furyl, where n can be 0-5 and in which phenyl, thienyl, pyridyl and furyl can in each case be substituted up to two times by Cl, F, CN, CF_3 , (C_1-C_3) -alkyl, OH, $O-(C_1-C_6)$ -alkyl;

R3

may be H, (C_1-C_6) -alkyl, F, CN, N_3 , $O-(C_1-C_6)$ -alkyl, $(CH_2)_n$ -phenyl, $(CH_2)_n$ -thienyl, $(CH_2)_n$ -pyridyl, $(CH_2)_n$ -furyl, where n can be 0-5 and in which phenyl, thienyl, pyridyl and furyl can in each case be substituted up to two times by Cl, F, CN, CF_3 , (C_1-C_3) -alkyl, OH, $O-(C_1-C_6)$ -alkyl;

may be $OC(O)CH_3$, (C_2-C_6) -alkynyl, (C_2-C_6) -alkenyl, $COO(C_1-C_6)$ -alkyl, $C(O)OH$, $C(O)NH_2$, $C(O)NHCH_3$, $C(O)N(CH_3)_2$;

R4

may be $(CH_2)_n-R_5$, where n can be 0-6;

R5 may be phenyl, biphenyl, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl or 2- or 3-thienyl;

and R5 may be substituted by

5 $\text{NH-SO}_2\text{-(C}_1\text{-C}_6\text{)-alkyl}$, $\text{NH-SO}_2\text{-phenyl}$, where the phenyl ring can be substituted up to two times by F, Cl, CN, OH, $(\text{C}_1\text{-C}_6\text{)-alkyl}$, $\text{O-(C}_1\text{-C}_6\text{)-alkyl}$, CF_3 , COOH , $\text{COO(C}_1\text{-C}_6\text{)-alkyl}$, CONH_2 ; $(\text{CH}_2)_n\text{-SO}_2\text{-(C}_1\text{-C}_6\text{)-alkyl}$, where n can be 1-6, $(\text{CH}_2)_m\text{-SO}_2\text{-NH}_2$, $(\text{CH}_2)_m\text{-SO}_2\text{-NH-(C}_1\text{-C}_6\text{)-alkyl}$,
10 $(\text{CH}_2)_m\text{-SO}_2\text{-N}[(\text{C}_1\text{-C}_6\text{)-alkyl}]_2$ or $(\text{CH}_2)_m\text{-SO}_2\text{-N(=CH-N(CH}_3\text{)}_2)$, where m can be 0-6;

and R5 can optionally additionally be substituted by F, Cl, Br, OH, CF_3 , CN, OCF_3 , $\text{O-(C}_1\text{-C}_6\text{)-alkyl}$, $(\text{C}_1\text{-C}_6\text{)-alkyl}$, $(\text{C}_3\text{-C}_6\text{)-cycloalkyl}$, COOH , $\text{COO(C}_1\text{-C}_6\text{)-alkyl}$, $\text{COO(C}_3\text{-C}_6\text{)-cycloalkyl}$, CONH_2 ,
15 $\text{CONH(C}_1\text{-C}_6\text{)-alkyl}$, $\text{CON}[(\text{C}_1\text{-C}_6\text{)-alkyl}]_2$, NH_2 , $\text{NH-CO-(C}_1\text{-C}_6\text{)-alkyl}$, NH-CO-phenyl , $(\text{CH}_2)_n\text{-phenyl}$, $\text{O-(CH}_2\text{)}_n\text{-phenyl}$, $\text{S-(CH}_2\text{)}_n\text{-phenyl}$, $\text{SO}_2\text{-(CH}_2\text{)}_n\text{-phenyl}$, where n can be 0-3;

and their physiologically acceptable salts and physiologically functional
20 derivatives.

Particular preference may be given to compounds of the formula I in which

R1, R1¹ independently of one another may be H, F, Cl, Br, I, CF_3 , NO_2 , CN,
25 COOH , $\text{COO(C}_1\text{-C}_6\text{)-alkyl}$, CONH_2 , $(\text{C}_1\text{-C}_6\text{)-alkyl}$, $(\text{C}_2\text{-C}_6\text{)-alkenyl}$, $(\text{C}_2\text{-C}_6\text{)-alkynyl}$, $\text{O-(C}_1\text{-C}_6\text{)-alkyl}$, $\text{SO}_2\text{-NH}_2$, phenyl, $\text{O-(CH}_2\text{)}_n\text{-phenyl}$, where n can be 0-6, where the phenyl rings can in each case be substituted one to 3 times by F, Cl, Br, I, OH, CF_3 , NO_2 , CN, OCF_3 ,

O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, NH₂, CONH₂;

R2 may be H, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, (CH₂)_n-phenyl, C(O)-(C₁-C₆)-alkyl, C(O)-(CH₂)_n-phenyl, where n can be 0-5 and in which phenyl can be substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH, O-(C₁-C₆)-alkyl;

R3 may be H, (C₁-C₆)-alkyl, F, (CH₂)_n-phenyl, where n can be 0-5 and in which phenyl can be substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH, O-(C₁-C₆)-alkyl;

may be COO(C₁-C₆)-alkyl, C(O)OH, C(O)NH₂;

R4 may be (CH₂)_n-R5, where n can be 0-6; or

15 R5 may be phenyl, 1- or 2-naphthyl;

and R5 may be substituted by

NH-SO₂-(C₁-C₆)-alkyl, NH-SO₂-phenyl, where the phenyl ring can be substituted up to two times by F, Cl, CN, OH, (C₁-C₆)-alkyl,

O-(C₁-C₆)-alkyl, CF₃, COOH, COO(C₁-C₆)-alkyl, CONH₂;

may be (CH₂)_n-SO₂-(C₁-C₆)-alkyl, where n can be 1-6,

may be (CH₂)_m-SO₂-NH₂, (CH₂)_m-SO₂-NH-(C₁-C₆)-alkyl, (CH₂)_m-SO₂-

N[(C₁-C₆)-alkyl]₂ or (CH₂)_m-SO₂-N(=CH-N(CH₃)₂), where m can be 0-6;

and R5 can optionally additionally be substituted by F, Cl, Br, OH, CF₃, CN, OCF₃,

O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, COOH, COO(C₁-C₆)-alkyl, CONH₂,

NH₂, NH-CO-(C₁-C₆)-alkyl, NH-CO-phenyl, (CH₂)_n-phenyl,

O-(CH₂)_n-phenyl, SO₂-(CH₂)_n-phenyl, where n can be 0-3;

and their physiologically acceptable salts.

A second aspect of the present invention provides a medicament, comprising one or more of the compounds of the formula I.

A third aspect of the present invention provides a medicament, comprising one or more of the compounds of the formula I and one or more anorectics.

A fourth aspect of the present invention provides a compound of the formula I for use as a medicament for the prophylaxis or treatment of obesity.

A fifth aspect of the present invention provides a compound of the formula I for use as a medicament for the prophylaxis or treatment of type II diabetes.

A sixth aspect of the present invention provides, a compound of the formula I in combination with at least one further anorectic for use as a medicament for the prophylaxis or treatment of obesity.

A seventh aspect of the present invention provides a compound of formula I in combination with at least one further anorectic for use as a medicament for the prophylaxis or treatment of type II diabetes.

An eighth aspect of the present invention provides a process for preparing a medicament comprising one or more of the compounds of formula I which comprises mixing the active compound with a pharmaceutically suitable excipient and bringing this mixture into a form suitable for administration.

A ninth aspect of the present invention provides the use of a compound of formula I for preparing a medicament for the prophylaxis or treatment of obesity.

A tenth aspect of the present invention provides the use of a compound of formula I for preparing a medicament for the prophylaxis or treatment of type II diabetes.

An embodiment may relate to compounds of the formula I, in the form of their

- 5 racemates, racemic mixtures and pure enantiomers, and to their diastereomers and mixtures thereof.

The alkyl, alkenyl and alkynyl radicals in the substituents R1, R1', R2, R3 and R5 can be either straight-chain or branched.

- 10 On account of their higher water solubility, pharmaceutically acceptable salts may be particularly suitable for medicinal applications compared with the starting materials or base compounds. These salts must have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as
- 15 hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid, and of organic acids, such as, for example, acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid,
- 20 p-toluenesulfonic acid, tartaric acid and trifluoroacetic acid. For medicinal purposes, the chlorine salt may be particularly preferred. Suitable pharmaceutically acceptable basic salts may be ammonium salts, alkali metal salts (such as sodium salts and potassium salts) and alkaline earth metal salts (such as magnesium salts and calcium salts).

25

Salts having a pharmaceutical unacceptable anion may likewise be included in the scope of the invention as useful intermediates for the production or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in-vitro, applications.

30

The term "physiologically functional derivative" used here may relate to any physiologically acceptable derivative of a compound of the formula I according to the invention, for example an ester, which, on administration to a mammal, such

The physiologically functional derivatives may also include prodrugs of the compounds.

The compounds can also be present in various

Hereinbelow, all references to "compound(s) according to formula (I)" may refer to a compound/compounds of the formula (I) as described above, and to their salts, solvates and physiologically functional derivatives as described herein.

The amount of a compound according to formula (I) which may be necessary in order to achieve the desired biological effect can be dependent on a number of factors, for example the specific compound selected, the intended use, the manner of administration and the clinical condition of the patient. In general, the daily dose may be in the range from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day per kilogram of body weight, for example 3-10 mg/kg/day. An intravenous dose can be, for example, in the range from 0.3 mg to 1.0 mg/kg, which can be suitably administered as an infusion of 10 ng to 100 ng per kilogram per minute. Suitable infusion solutions for these purposes can contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter. Individual doses can contain, for example, from 1 mg to 10 g of the active compound. Thus, ampoules for injections can contain, for example, from 1 mg to 100 mg, and orally administrable individual dose formulations, such as, for example, tablets or capsules, can contain, for example, from 1.0 to 1 000 mg, typically from 10 to 600 mg. In the case of pharmaceutically acceptable salts, the abovementioned weight details may relate to the weight of the dihydrothiazolium ion derived from the salt. For the prophylaxis or

- therapy of the abovementioned conditions, the compounds according to formula (I) can be used themselves as the compound, but they may preferably be present in the form of a pharmaceutical composition with a tolerable excipient. The excipient must of course be tolerable, in the sense that it may be compatible with the other constituents of the composition and may not be harmful to the patient's health. The excipient can be a solid or a liquid or both and may be preferably formulated with the compound as an individual dose, for example as a tablet which can contain from 0.05% to 95% by weight of the active compound. Further pharmaceutically active substances can also be present, including further compounds according to formula (I). The pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which may essentially consist in mixing the constituents with pharmacologically acceptable excipients and/or auxiliaries.

Pharmaceutical compositions according to one embodiment may be those which are suitable for oral, rectal, topical, peroral (e.g. sublingual) and parental (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable manner of administration in each individual case may be dependent on the nature and severity of the condition to be treated and on the nature of the compound according to formula (I) used in each case. Sugar-coated formulations and sugar-coated delayed release formulations may also be included in one embodiment. Acid-resistant and enteric formulations may be preferred. Suitable enteric coatings may include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.

25

- Suitable pharmaceutical compounds for oral administration can be present in separate units, such as, for example, capsules, cachets, lozenges or tablets which in each case may contain a certain amount of the compound according to formula (I); as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared by any suitable pharmaceutical method which may includes a step in which the active compound and the excipient (which can consist of one or more additional constituents) are brought into contact. In general, the

30

compositions may be prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid excipient, after which the product may be shaped, if necessary. Thus a tablet, for example, can be prepared by pressing or shaping a powder or granules of the compound, if appropriate with one or more additional constituents. Pressed tablets can be prepared by tableting the compound in free-flowing form, such as, for example, in a powder or granules, if appropriate mixed with a binder, lubricant, inert diluent and/or one (a number of) surface-active/dispersing agent(s) in a suitable machine. Shaped tablets can be prepared by shaping the pulverulent compound, moistened with an inert liquid diluent, in a suitable machine.

Pharmaceutical compositions which may be suitable for peroral (sublingual) administration may include lozenges which may contain a compound according to formula (I) with a flavoring, customarily sucrose and gum arabic or tragacanth, and pastilles which may include the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.

Suitable pharmaceutical compositions for parenteral administration may preferably include sterile aqueous preparations of a compound according to formula (I), which may be preferably isotonic with the blood of the intended recipient. These preparations may preferably be administered intravenously, although the administration can also take place subcutaneously, intramuscularly or intradermally as an injection. These preparations can preferably be prepared by mixing the compound with water and rendering the obtained solution sterile and isotonic with the blood. Injectable compositions according to one embodiment in general may contain from 0.1 to 5% by weight of the active compound.

Suitable pharmaceutical compositions for rectal administration may be preferably present as individual dose suppositories. These can be prepared by mixing a compound according to formula (I) with one or more conventional solid excipients, for example cocoa butter, and shaping the resulting mixture.


Suitable pharmaceutical compositions for topical application to the skin may be preferably present as ointment, cream, lotion, paste, spray, aerosol or oil.

Excipients which can be used are petroleum jelly, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active compound may be in general present in a concentration of from 0.1 to 15%, for example of from 0.5 to 2%, by weight of the composition.

Transdermal administration may also be possible. Suitable pharmaceutical compositions for transdermal administration can be present as individual patches which may be


- 10 suitable for long-term close contact with the epidermis of the patient. Such patches may suitably contain the active compound in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active compound concentration may be from about 1% to 35%, preferably from about 3% to 15%. As a particular possibility, the active compound can be released by
- 15 electrotransport or iontophoresis, as described, for example, in *Pharmaceutical Research*, 2(6): 318 (1986).

An eleventh aspect of the present invention furthermore provide a process for preparing the compounds of the formula I, which comprises obtaining the compounds of the formula I in such a way that the procedure is according to the following reaction scheme:




To this end, compounds of the formula II,

13



formula II

in which R1 and R1' are as defined above, are reacted with bromine to give a compound of the formula III in which R3 is as defined for formula I. Compounds of the formula III are then reacted with thiomides of the formula IV



IV

10

in which R4 is as defined for compounds of the formula I in which R2 is hydrogen, For their part, these compounds can be converted by standard methods into compounds of the formula I in which R2 is as defined for formula I.

15

The compounds of the formula I can also be present as salts with acids. Suitable inorganic acids are, for example: hydrohalic acids, such as hydrochloric acid and hydrobromic acid, and also sulfuric acid, phosphoric acid and amidosulfonic acid.

20

Organic acids which may be mentioned are, for example: formic acid, acetic acid, benzoic acid, p-toluenesulfonic acid, benzenesulfonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, citric acid, L-ascorbic acid, salicylic acid, isethionic acid, methanesulfonic acid, trifluoromethanesulfonic acid, 1,2-benzisothiazol-3(2H)-one, 6-methyl-1,2,3-oxathiazin-4(3H)-one 2,2-dioxide.

25

The procedure described above may be advantageously carried out such that the compounds III may react with the thioamides IV in a molar ratio of from 1:1 to

1:1.5. The reaction may be advantageously carried out in an inert solvent, for example in polar organic solvents, such as dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, dioxane, tetrahydrofuran, acetonitrile, nitromethane or diethylene glycol dimethyl ether. Particularly advantageous solvents, however, may have proved to be methyl acetate and ethyl acetate, short-chain alcohols, such as methanol, ethanol, propanol, isopropanol, and lower dialkyl ketones, such as, for example, acetone, butan-2-one or hexan-2-one. Mixtures of the reaction media mentioned can also be used; and mixtures of the solvents mentioned with solvents which, taken per se, may be less suitable, such as, for example, mixtures of methanol with benzene, ethanol with toluene, methanol with diethyl ether or with tert-butyl methyl ether, ethanol with carbon tetrachloride, acetone with chloroform, dichloromethane or 1,2-dichloroethane, can also be used, where the more polar solvent in each case should expediently be used in an excess. The reactants can be suspended or dissolved in the respective reaction medium. In principle, the reactants can also be reacted in the absence of a solvent, in particular if the respective thiomide may have a melting point which may be as low as possible. The reaction may proceed in an only slightly exothermic manner and can be carried out between -10°C and 150°C ; preferably between 30°C and 100°C . A temperature range between 50°C and 90°C may have generally been found to be particularly favorable.

The reaction time may be largely dependent on the reaction temperature and may be between 2 minutes and 3 days at relatively high and relatively low temperatures, respectively. In the favorable temperature range, the reaction time may be generally between 5 minutes and 48 hours.

In the course of the reaction, the compounds I may frequently form a poorly soluble deposit in the form of their acid addition salts, expediently a suitable precipitating agent may be additionally subsequently added. Those used are, for example, hydrocarbons such as benzene, toluene, cyclohexane or heptane or carbon tetrachloride; in particular, alkyl acetates, such as ethyl acetate or n-butyl acetate, or dialkyl ethers, such as diethyl ether, diisopropyl ether, di-n-butyl ether or tert-butyl methyl ether may prove particularly suitable. If the reaction mixture remains in solution after the end of the reaction, the salts of the compounds I can be

precipitated using one of the precipitating agents mentioned, if appropriate after concentration of the reaction solution. Furthermore, the solution of the reaction mixture can also be advantageously filtered into the solution of one of the precipitating agents mentioned, with stirring. Work-up of the reaction mixture can also be carried out such that the reaction mixture may be rendered alkaline by addition of an organic base, such as, for example, triethylamine or diisobutylamine or ammonia or morpholine or piperidine or 1,8-diazabicyclo[5.4.0]undec-7-ene, and the crude reaction product may be purified chromatographically, for example on a silica gel column, after concentration. Suitable eluents for this prove to be, for example, mixtures of ethyl acetate with methanol, mixtures of dichloromethane with methanol, mixtures of toluene with methanol or ethyl acetate or mixtures of ethyl acetate with hydrocarbons such as heptane. If the purification of the crude product may be carried out in the manner last described, an acid addition product of the formula I can be obtained from the pure base of the formula I thus obtained by dissolving or suspending the base in an organic protic solvent, such as methanol, ethanol, propanol or isopropanol, or in an organic aprotic solvent, such as ethyl acetate, diethyl ether, diisopropyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, acetone or butan-2-one, and then treating this mixture with an at least equimolar amount of an inorganic acid such as, for example, hydrochloric acid, dissolved in an inert solvent such as, for example, diethyl ether or ethanol, or another of the inorganic or organic acids mentioned further above.

The compounds of the formula I can be recrystallized from an inert suitable solvent such as, for example, acetone, butan-2-one, acetonitrile or nitromethane.

However, particularly advantageous may be the precipitation from a solvent such as, for example, dimethylformamide, dimethylacetamide, nitromethane, acetonitrile, preferably methanol or ethanol.


The reaction of the compounds of the formula III with the thioamides of the formula IV can also be carried out such that an at least equimolar amount of a base, such as, for example, triethylamine, may be added to the reaction mixture and the resulting compounds I may then be optionally converted into their acid addition products.

By treatment with bases, the acid addition products I can be converted into the compounds of the formula I (free base). Suitable bases are, for example, solutions

of inorganic hydroxides, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide or barium hydroxide, carbonates or hydrogen carbonates, such as sodium carbonate or potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate, ammonia and amines, such as
 5 triethylamine, diisopropylamine, dicyclohexylamine, piperidine, morpholine, methyldicyclohexylamine.

Thiomides of the formula IV may either be commercially available or can be obtained, for example, by reaction of the corresponding carboxamide with phosphorus
 10 pentasulfide in pyridine (R. N. Hurd, G. Delameter, Chem. Rev. 61, 45 (1961)), or with Lawesson's reagent in toluene, pyridine, hexamethylphosphoric triamide [Scheibye, Pedersen and Lawesson: Bull. Soc. Chim. Belges 87, 229 (1978)], preferably in a mixture of tetrahydrofuran with 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone or 1,3-dimethyl-2-imidazolidinone. Hydroxyl, amino or additional carbonyl functions may be in this case expediently protected using a removable protective function, such as, for example, a benzyl, tert-butylloxycarbonyl or benzyloxycarbonyl radical, or converted into an optionally cyclic acetal. Methods for this are described, for example, in Th. W. Greene and
 20 P. G. M. Wuts, Protective Groups in Organic Synthesis, Second Edition, 1991, John Wiley & Sons, New York.

Thioamides of the formula IV can also be obtained by reacting nitriles of the formula VII




formula VII

with hydrogen sulfide (Houben-Weyl IX, 762) or thioacetamide (E. C. Taylor, J. A. Zoltewicz, J. Am. Chem. Soc. 82, 2656 (1960)) or O,O-diethyl dithiophosphoric acid. The reactions with hydrogen sulfide may preferably be carried out in an organic
 30 solvent, such as methanol or ethanol, those with thioacetamide in a solvent such as dimethylformamide with addition of hydrochloric acid, and those with

O,O-diethyl dithiophosphoric acid in a solvent such as ethyl acetate under acidic, e.g. HCl, conditions at room temperature or with warming.

The examples given below may serve to illustrate the invention, but without restricting it. The measured melting or decomposition points (m.p.) were not corrected and may be generally dependent on the heating rate.

Table 1: Examples



formula I

Example	R1; R1'	R2	R3	R4	Salt	m.p. [°C]
1	6-Cl; H	H	H	(C ₆ H ₄)-4-NH-SO ₂ -(C ₆ H ₄)-4-Cl	-	116
2	6-Cl; H	H	H	(C ₆ H ₄)-4-(NH-SO ₂ -CH ₃)	-	166
3	6-Cl; H	H	H	(C ₆ H ₃)-3-(SO ₂ -N=CH-N(CH ₃) ₂)- 4-Cl	-	180
4	6-Cl; H	H	H	(C ₆ H ₃)-3-(SO ₂ -NH ₂)-4-Cl	-	148
5	6-Cl; H	H	H	(C ₆ H ₄)-4-(SO ₂ -NH ₂)	-	160
6	H; H	H	H	(C ₆ H ₄)-4-(SO ₂ -NH ₂)	HBR	250

The compounds of the formula I are distinguished by favorable effects on lipid metabolism; in particular, they are suitable as anorectics. The compounds can be employed on their own or in combination with other anorectically active compounds. Such further anorectically active compounds are mentioned, for example, in the Rote Liste, chapter 01 under slimming preparations/anorectics.

The compounds are suitable for the prophylaxis and in particular for the treatment of obesity. The compounds are furthermore suitable for the prophylaxis and in particular for the treatment of type II diabetes.


The efficacy of the compounds was tested as follows:

Biological test model:

The anorectic action was tested on male or female NMRI mice. After withdrawal of feed for 24 hours, the test preparation was administered via a stomach tube. Kept individually and with free access to drinking water, the animals were offered evaporated milk 30 minutes after the administration of the preparation. The consumption of evaporated milk was determined half-hourly for 3 hours and the

general condition of the animals was observed. The measured milk consumption was compared with that of untreated control animals.

Table 2: Anorectic action, measured as reduction of the cumulated milk consumption of treated animals compared with untreated animals.

Compound/example  formula I	Oral dose [mg/kg]	Number of animals / cumulated milk consumption of the treated animals	Number of animals / cumulated milk consumption of the untreated control animals	Reduction of the cumulated milk consumption in % of the control
		N / [ml]	N / [ml]	
Example 4	50	female animals 5 / 0.82	female animals 5 / 2.66	69
Example 5	50	male animals 5 / 0.08	male animals 5 / 1.54	95
Example 6	50	male animals 5 / 1.26	male animals 5 / 5.10	76

It can be inferred from the table that the compounds of the formula I exhibit very good anorectic action.

The preparation of some examples is described in detail below; the other compounds of the formula I were obtained in a similar manner:

Example 1 (Compound 1):

4-Chloro-N-[4-(6-chloro-3a-hydroxy-8,8a-dihydro-3aH-indeno[1,2-d]thiazol-2-yl)-phenyl]benzenesulfonamide:

5

a) 2-Bromo-5-chloroindan-1-one:

10

10 g (0.06 mol) of 5-chloroindan-1-one are dissolved with stirring at room temperature in 120 ml of glacial acetic acid. 0.05 ml of a 48% strength solution of HBr in water and then 3.074 ml (0.06 mol) of bromine, dissolved in 25 ml of glacial acetic acid, are added dropwise. The reaction has ended after 2 h of stirring at room temperature (TLC). The solution of the crude product is, with stirring, slowly added dropwise to 300 ml of ice-water. The precipitated crude product is filtered off with suction and washed thoroughly with water. The moist residue is removed from the filter using ethyl acetate, and the phases of the filtrate are separated. The organic phase is dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue is dissolved in 120 ml of hot n-heptane; the hot solution is filtered through a pleated filter and the solution is then left to crystallize at 0°C. The crystallized product is filtered off with suction and dried under reduced pressure.

15

20

M.p.: 94-96°C

b) 4-(4-Chlorobenzenesulfonylamino)thiobenzamide:

25

0.26 g of 4-chloro-4'-cyanobenzenesulfonamide are suspended in 10 ml of absolute ethanol and admixed with 0.15 ml of diethyl dithiophosphate, and the mixture is stirred under reflux for 8 h. Another portion of 0.15 ml of diethyl dithiophosphate is then added, and the mixture is stirred at reflux temperature for a further 12 h. The cooled reaction mixture is concentrated under reduced pressure; the residue is stirred with dichloromethane and the solid residue is filtered off with suction, washed with dichloromethane and dried under reduced pressure. The resulting 4-(4-chlorobenzenesulfonylamino)thiobenzamide is used for the next step without any further purification.

30

- c) 4-Chloro-N-[4-(6-chloro-3a-hydroxy-8,8a-dihydro-3aH-indeno[1,2-d]thiazol-2-yl)phenyl]benzenesulfonamide:

5 At room temperature, 0.15 g of the compound from Example 1b and 0.11 g of the compound from Example 1a are dissolved in 5 ml of dry acetone, and the mixture is then stirred at room temperature for 4 h. 65 μ l of triethylamine are added, and the mixture is stirred at room temperature overnight.

10 Another 20 μ l of triethylamine are added, and the mixture is stirred at room temperature for another night. The reaction mixture is then concentrated under reduced pressure; the residue is dissolved in ethyl acetate, washed twice with water and once with sat. sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue is purified by silica gel chromatography using toluene/acetone 3/1.


15 This gives 4-chloro-N-[4-(6-chloro-3a-hydroxy-8,8a-dihydro-3aH-indeno[1,2-d]thiazol-2-yl)phenyl]benzenesulfonamide of melting point 116°C.

Example 2 (Compound 6):

4-(6-Chloro-3a-hydroxy-8,8a-dihydro-3aH-indeno[1,2-d]thiazol-2-yl)benzene-sulfonamide is prepared in a similar manner by reacting 2-bromo-5-chloroindan-1-one with 4-sulfamoylthiobenzamide. The compound has a melting point of 160°C.

Patent claims:

1. A compound of the formula I



I

in which

- 10 R1, R1' independently of one another are H, F, Cl, Br, I, CF₃, NO₂, CN, COOH, COO(C₁-C₆)-alkyl, CONH₂, CONH(C₁-C₆)-alkyl, CON[(C₁-C₆)-alkyl]₂, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, O-(C₁-C₆)-alkyl, where in the alkyl radicals one or more, or all the hydrogen(s) may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH₃, OC(O)H, O-CH₂-Ph, NH₂, NH-CO-CH₃ or N(COOCH₂Ph)₂;
- 15 are SO₂-NH₂, SO₂NH(C₁-C₆)-alkyl, SO₂N[(C₁-C₆)-alkyl]₂, S-(C₁-C₆)-alkyl, S-(CH₂)_n-phenyl, SO-(C₁-C₆)-alkyl, SO-(CH₂)_n-phenyl, SO₂-(C₁-C₆)-alkyl, SO₂-(CH₂)_n-phenyl, where n can be 0-6 and the phenyl radical can be substituted up to two times by F, Cl, Br, OH, CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, NH₂;
- 20 are NH₂, NH-(C₁-C₆)-alkyl, N[(C₁-C₆)-alkyl]₂, NH(C₁-C₇)-acyl, phenyl, biphenyl, O-(CH₂)_n-phenyl, where n can be 0-6, 1- or

2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl or 2- or 3-thienyl, where the phenyl, biphenyl, naphthyl, pyridyl, furanyl or thienyl rings can in each case be substituted one to three times by F, Cl, Br, I, OH, CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, NH₂, NH(C₁-C₆)-alkyl, N[(C₁-C₆)-alkyl]₂, SO₂-CH₃, COOH, COO-(C₁-C₆)-alkyl, CONH₂;

are 1,2,3-triazol-5-yl, where the triazole ring can be substituted in the 1-, 2- or 3-position by methyl or benzyl;

are tetrazol-5-yl, where the tetrazole ring can be substituted in the 1- or 2-position by methyl or benzyl;

R₂ is H, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, (CH₂)_n-phenyl, (CH₂)_n-thienyl, (CH₂)_n-pyridyl, (CH₂)_n-furyl, C(O)-(C₁-C₆)-alkyl, C(O)-(C₃-C₆)-cycloalkyl, C(O)-(CH₂)_n-phenyl, C(O)-(CH₂)_n-thienyl, C(O)-(CH₂)_n-pyridyl, C(O)-(CH₂)_n-furyl, where n can be 0-5 and in which phenyl, thienyl, pyridyl and furyl can in each case be substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH, O-(C₁-C₆)-alkyl;

20 R₃ is H, (C₁-C₆)-alkyl, F, CN, N₃, O-(C₁-C₆)-alkyl, (CH₂)_n-phenyl, (CH₂)_n-thienyl, (CH₂)_n-pyridyl, (CH₂)_n-furyl, where n can be 0-5 and in which phenyl, thienyl, pyridyl and furyl can in each case be substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH, O-(C₁-C₆)-alkyl;

25 is OC(O)CH₃, (C₂-C₆)-alkynyl, (C₂-C₆)-alkenyl, COO(C₁-C₆)-alkyl, C(O)OH, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂;

R₄ is (CH₂)_n-R₅, where n can be 0-6;

R5 is phenyl, biphenyl, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl, 1-pyrazolyl, 3- or 5-isoxazolyl, 2- or 3-pyrrolyl, 2- or 3-pyridazinyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, 2-(1,3,5-triazinyl), 2- or 5-benzimidazolyl, 2-benzothiazolyl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, tetrazol-5-yl, indol-3-yl, indol-5-yl or N-methylimidazol-2-, -4- or -5-yl;

and R5 is substituted by

NH-SO₂-(C₁-C₆)-alkyl, NH-SO₂-phenyl, where the phenyl ring can be substituted up to two times by F, Cl, CN, OH, (C₁-C₆)-alkyl,

O-(C₁-C₆)-alkyl, CF₃, COOH, COO(C₁-C₆)-alkyl, CONH₂;

(CH₂)_n-SO₂-(C₁-C₆)-alkyl, where n can be 1-6,

(CH₂)_m-SO₂-NH₂, (CH₂)_m-SO₂-NH-(C₁-C₆)-alkyl, (CH₂)_m-SO₂-

N[(C₁-C₆)-alkyl]₂ or (CH₂)_m-SO₂-N(=CH-N(CH₃)₂), where m can be 0-6;

and R5 can optionally additionally be substituted by F, Cl, Br, OH, CF₃, NO₂, CN,

OCF₃, O-(C₁-C₆)-alkyl, S-(C₁-C₆)-alkyl, SO-(C₁-C₆)-alkyl,

(C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, COOH, COO(C₁-C₆)-alkyl,

COO(C₃-C₆)-cycloalkyl, CONH₂, CONH(C₁-C₆)-alkyl,

CON[(C₁-C₆)-alkyl]₂, CONH(C₃-C₆)-cycloalkyl, NH₂,

NH-CO-(C₁-C₆)-alkyl, NH-CO-phenyl, pyrrolidin-1-yl, morpholin-1-yl,

piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH₂)_n-phenyl,

O-(CH₂)_n-phenyl, S-(CH₂)_n-phenyl, SO₂-(CH₂)_n-phenyl, where n can be 0-3;

and its physiologically acceptable salts and physiologically functional derivatives.

2. A compound of the formula I as claimed in claim 1, wherein

R1, R¹ independently of one another are H, F, Cl, Br, I, CF₃, NO₂, CN, COOH, COO(C₁-C₆)-alkyl, CONH₂, CONH(C₁-C₆)-alkyl, CON[(C₁-C₆)-alkyl]₂, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, O-(C₁-C₆)-alkyl, where in the alkyl radicals one hydrogen may be replaced by OH, OC(O)CH₃, OC(O)H, O-CH₂-Ph, NH₂, NH-CO-CH₃ or N(COOCH₂Ph)₂;

is SO₂-NH₂, SO₂NH(C₁-C₆)-alkyl, SO₂N[(C₁-C₆)-alkyl]₂, S-(C₁-C₆)-alkyl, S-(CH₂)_n-phenyl, SO-(C₁-C₆)-alkyl, SO-(CH₂)_n-phenyl,

SO₂-(C₁-C₆)-alkyl, SO₂-(CH₂)_n-phenyl, where n can be 0-6 and the phenyl radical can be substituted up to two times by F, Cl, Br, OH, CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, NH₂;

is NH₂, NH-(C₁-C₆)-alkyl, N[(C₁-C₆)-alkyl]₂, NH(C₁-C₇)-acyl, phenyl, biphenyl, O-(CH₂)_n-phenyl, where n can be 0-6, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl or 2- or 3-thienyl where the phenyl, biphenyl, naphthyl, pyridyl, furanyl or thienyl rings can in each case be substituted one to 3 times by F, Cl, Br, I, OH, CF₃, NO₂, CN,

OCF₃, O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, NH₂, NH(C₁-C₆)-alkyl,

N[(C₁-C₆)-alkyl]₂, SO₂-CH₃, COOH, COO-(C₁-C₆)-alkyl, CONH₂;

are 1,2,3-triazol-5-yl, where the triazole ring can be substituted in the 1-, 2- or 3-position by methyl or benzyl;

are tetrazol-5-yl, where the tetrazole ring can be substituted in the 1- or 2-position by methyl or benzyl;

R2 is H, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, (CH₂)_n-phenyl, (CH₂)_n-thienyl,

(CH₂)_n-pyridyl, (CH₂)_n-furyl, C(O)-(C₁-C₆)-alkyl, C(O)-(C₃-C₆)-cycloalkyl, C(O)-(CH₂)_n-phenyl, C(O)-(CH₂)_n-thienyl,

C(O)-(CH₂)_n-pyridyl, C(O)-(CH₂)_n-furyl, where n can be 0-5 and in

which phenyl, thienyl, pyridyl and furyl can in each case be substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH, O-(C₁-C₆)-alkyl;

5 R3 is H, (C₁-C₆)-alkyl, F, CN, N₃, O-(C₁-C₆)-alkyl, (CH₂)_n-phenyl, (CH₂)_n-thienyl, (CH₂)_n-pyridyl, (CH₂)_n-furyl, where n can be 0-5 and in which phenyl, thienyl, pyridyl and furyl can in each case be substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH, O-(C₁-C₆)-alkyl;

10 is OC(O)CH₃, (C₂-C₆)-alkynyl, (C₂-C₆)-alkenyl, COO(C₁-C₆)-alkyl, C(O)OH, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂;

R4 is (CH₂)_n-R5, where n can be 0-6;

15 R5 is phenyl, biphenyl, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl or 2- or 3-thienyl;

and R5 is substituted by

NH-SO₂-(C₁-C₆)-alkyl, NH-SO₂-phenyl, where the phenyl ring can be substituted up to two times by F, Cl, CN, OH, (C₁-C₆)-alkyl,

20 O-(C₁-C₆)-alkyl, CF₃, COOH, COO(C₁-C₆)-alkyl, CONH₂;

(CH₂)_n-SO₂-(C₁-C₆)-alkyl, where n can be 1-6,

(CH₂)_m-SO₂-NH₂, (CH₂)_m-SO₂-NH-(C₁-C₆)-alkyl,

(CH₂)_m-SO₂-N[(C₁-C₆)-alkyl]₂ or (CH₂)_m-SO₂-N(=CH-N(CH₃)₂), where m can be 0-6;

25 and R5 can optionally additionally be substituted by F, Cl, Br, OH, CF₃, CN, OCF₃,

O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, COOH,

COO(C₁-C₆)-alkyl, COO(C₃-C₆)-cycloalkyl, CONH₂,

CONH(C₁-C₆)-alkyl, CON[(C₁-C₆)-alkyl]₂, NH₂, NH-CO-(C₁-C₆)-alkyl, NH-CO-phenyl, (CH₂)_n-phenyl, O-(CH₂)_n-phenyl, S-(CH₂)_n-phenyl, SO₂-(CH₂)_n-phenyl, where n can be 0-3;

5 and its physiologically acceptable salts and physiologically functional derivatives.

3. A compound of the formula I as claimed in claim 1 or 2, wherein

10 R₁, R₁['] independently of one another are H, F, Cl, Br, I, CF₃, NO₂, CN, COOH, COO(C₁-C₆)-alkyl, CONH₂, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, O-(C₁-C₆)-alkyl, SO₂-NH₂, phenyl, O-(CH₂)_n-phenyl, where n can be 0-6, where the phenyl rings can in each case be substituted one to 3 times by F, Cl, Br, I, OH, CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, NH₂, CONH₂;

15 R₂ is H, (C₁-C₆)-alkyl, (C₃-C₆)-cycloalkyl, (CH₂)_n-phenyl, C(O)-(C₁-C₆)-alkyl, C(O)-(CH₂)_n-phenyl, where n can be 0-5 and in which phenyl can be substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH, O-(C₁-C₆)-alkyl;

20 R₃ is H, (C₁-C₆)-alkyl, F, (CH₂)_n-phenyl, where n can be 0-5 and in which phenyl can be substituted up to two times by Cl, F, CN, CF₃, (C₁-C₃)-alkyl, OH, O-(C₁-C₆)-alkyl; is COO(C₁-C₆)-alkyl, C(O)OH, C(O)NH₂;

25 R₄ is (CH₂)_n-R₅, where n can be 0-6; or

R₅ is phenyl, 1- or 2-naphthyl;

and R5 is substituted by

NH-SO₂-(C₁-C₆)-alkyl, NH-SO₂-phenyl, where the phenyl ring can be substituted up to two times by F, Cl, CN, OH, (C₁-C₆)-alkyl,

O-(C₁-C₆)-alkyl, CF₃, COOH, COO(C₁-C₆)-alkyl, CONH₂;

5 is (CH₂)_n-SO₂-(C₁-C₆)-alkyl, where n can be 1-6,

is (CH₂)_m-SO₂-NH₂, (CH₂)_m-SO₂-NH-(C₁-C₆)-alkyl, (CH₂)_m-SO₂-

N[(C₁-C₆)-alkyl]₂ or (CH₂)_m-SO₂-N(=CH-N(CH₃)₂), where m can be 0-6;

and R5 can optionally additionally be substituted by F, Cl, Br, OH, CF₃, CN, OCF₃,

10 O-(C₁-C₆)-alkyl, (C₁-C₆)-alkyl, COOH, COO(C₁-C₆)-alkyl, CONH₂,

NH₂, NH-CO-(C₁-C₆)-alkyl, NH-CO-phenyl, (CH₂)_n-phenyl,

O-(CH₂)_n-phenyl, SO₂-(CH₂)_n-phenyl, where n can be 0-3;

and its physiologically acceptable salts.

15

4. A medicament, comprising one or more of the compounds as claimed in one or more of claims 1 to 3.

5. A medicament, comprising one or more of the compounds as claimed in
20 one or more of claims 1 to 3 and one or more anorectics.

6. A compound as claimed in one or more of claims 1 to 3 for use as a medicament for the prophylaxis or treatment of obesity.

25 7. A compound as claimed in one or more of claims 1 to 3 for use as a medicament for the prophylaxis or treatment of type II diabetes.

8. A compound as claimed in one or more of claims 1 to 3 in combination with at least one further anorectic for use as a medicament for the prophylaxis or
30 treatment of obesity.

9. A compound as claimed in one or more of claims 1 to 3 in combination with at least one further anorectic for use as a medicament for the prophylaxis or treatment of type II diabetes.

5

10. A process for preparing a medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 3, which comprises mixing the active compound with a pharmaceutically suitable excipient and bringing this mixture into a form suitable for administration.


10

11. The use of a compound as claimed in one or more of claims 1 to 3 for preparing a medicament for the prophylaxis or treatment of type II diabetes.

12. The use of a compound as claimed in one or more of claims 1 to 3 for preparing a medicament for the prophylaxis or treatment of type II diabetes.

15

13. A process for preparing a compound as claimed in one or more of claims 1 to 3, which comprises reacting, according to the following reaction scheme,



20

a compound of the formula II in which R1 and R1' and R3 are as defined for formula I with bromine to give a compound III in which R1, R1' and R3 are as defined for formula I, and reacting the compound of the formula III further with thioamides of the formula IV in which R4 is as defined for formula I to give a compound of the formula I.

25